Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)
Interventions: PROCEDURE: Cardiac MRI|BIOLOGICAL: Biomarker Testing
Sponsor: Unity Health Toronto
Collaborators: Hoffmann-La Roche